<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04541771</url>
  </required_header>
  <id_info>
    <org_study_id>CH&amp;ICH</org_study_id>
    <nct_id>NCT04541771</nct_id>
  </id_info>
  <brief_title>The Role of Lactobacillus Reuteri in Preventing Necrotizing Enterocolitis (NEC) in Pre-term Infants</brief_title>
  <acronym>NEC</acronym>
  <official_title>The Role of Lactobacillus Reuteri (L. Reuteri) in Preventing Necrotizing Enterocolitis (NEC) in Pre-term Infants Less Than 34 Weeks of Gestation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital and Institute of Child Health, Multan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital and Institute of Child Health, Multan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effectiveness of L. Reuteri with placebo in&#xD;
      prevention of NEC in children, as according to my knowledge, there is limited work is done&#xD;
      nationally and internationally. Probiotics are being used in our Children Hospital and the&#xD;
      Institute of Child Health, Multan.&#xD;
&#xD;
      Route of administration of L. Reuteri will be oral or via nasogastric tube due to&#xD;
      availability of oral form in Pakistan. The results of this study will be helpful to assess&#xD;
      the beneficial effects of probiotics especially L. Reuteri in NEC in preterm. So, they can be&#xD;
      recommended as preventive strategy to avoid NEC development and its complications based on&#xD;
      its availability, effectivity and easy administration&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>participants will be divided in two groups. one is control group and the other Interventional group. control group will receive the drug under study and control will be given placebo for the period of until they complete 35 weeks of gestation or discharged.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>narcotizing enterocolitis</measure>
    <time_frame>up to 35 weeks of gestation</time_frame>
    <description>number of participants with the sign of feeding intolerance (such as the gastric aspirate in the amount that was more than half of previous feeding), or with abdominal distension measured by increase in abdominal girth from base line,Bell Staging Criteria according to clinical and radio-logical signs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>sepsis</measure>
    <time_frame>At time of addmission and 15 days after intervention</time_frame>
    <description>number of participants who developed sepsis proven by blood cultures before of after intervention</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Necrotizing Enterocolitis</condition>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>drug group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The trial group will receive their usual feeds plus daily probiotic (Lactobacillus Reuteri DSM 17938) addition 1 drop/kg/dose(. minimum of 20 million live Lactobacillus Reuteri are present in One drop) twice daily added in expressed breast milk/formula milk from the beginning of enteral feedings till the baby attain full feeds</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>this group is control group and will receive normal saline drops as 1 drop/kg/ dose mixed in enteral feed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactobacillus Reuteri DSM 17938</intervention_name>
    <description>The trial group will receive their usual feeds plus daily probiotic addition 1 drop/kg/dose twice daily added in expressed breast milk/formula milk from the beginning of enteral feedings till the baby attain full feeds</description>
    <arm_group_label>drug group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>expressed breast milk/formula milk plus normal saline drop from the beginning of enteral feedings till the baby attain full feeds</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Preterm neonate&lt; 34 weeks and &gt;28 weeks of gestation of both genders Hemodynamically&#xD;
             stable&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Preterm neonates &gt;34 weeks gestational age &lt; 28 weeks of gestation Cardiorespiratory&#xD;
             illness Parental refusal&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>28 Weeks</minimum_age>
    <maximum_age>34 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>summera tabasum</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH&amp;ICH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>STabasum</last_name>
    <phone>03417236837</phone>
    <email>dr.sumeratabasum@gmail.com</email>
  </overall_contact>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 5, 2020</study_first_submitted>
  <study_first_submitted_qc>September 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2020</study_first_posted>
  <last_update_submitted>September 7, 2020</last_update_submitted>
  <last_update_submitted_qc>September 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital and Institute of Child Health, Multan</investigator_affiliation>
    <investigator_full_name>Dr Summera Tabasum</investigator_full_name>
    <investigator_title>post-graduate resident</investigator_title>
  </responsible_party>
  <keyword>Necrotizing Enterocolitis,</keyword>
  <keyword>lactobacillus reuteri ds 17938</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enterocolitis</mesh_term>
    <mesh_term>Enterocolitis, Necrotizing</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

